Tuesday, December 16, 2025 12/16/2025

A framework for integrating MR imaging and clinical tests for prediction of outcomes in multiple myeloma treatment

Award Number: R01CA278898
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/01/2023
PERIOD OF PERFORMANCE END DATE: 11/30/2028

Group Awards By:

View Award Description

A framework for integrating MR imaging and clinical tests for prediction of outcomes in multiple myeloma treatment - Abstract Multiple myeloma (MM) is the second most common hematologic malignancy (after non-Hodgkin lymphoma) in the U.S. Over the past decade, despite the advent of novel therapies that has improved the life expectancy of patients with MM, MM is still incurable. Patient outcome varies widely with overall survival (OS) ranging from less than 1 year to greater than 10 years. The large variability of patient overall survival resulting from the high heterogeneous microenvironment of MM heightens the needs of risk-adapted treatment for long-term control, which are largely relied on accurate assessment of tumor evolution and survival prediction. The International Myeloma Working Group (IMWG) guideline and several other different prognostic models have been used to assess treatment outcomes. These systems utilize different subsets of laboratory values from clinic tests as assessment criteria, which may not indicate the full extent of tumor burden. MRI is the gold standard imaging modality for detection of bone marrow involvement. It provides global representation of the tumor burden, even for patient with non-secretory or hypo-secretory MM. We hypothesize that integrating multimodal information delivered by time serial noninvasive MR imaging and clinical tests will provide more robust and accurate modeling of MM evolution during and after treatment, and thus can predict treatment outcomes more reliably at an early time. Our goal is to develop a framework of decision support system (DSS) that integrates MR images and clinical tests to assist physicians in making informed decisions on tailoring treatment for an individual MM patient. The proposed study aims to (1) Investigate the effectiveness of MRI radiomic features in characterizing MM infiltration and their correlations with treatment outcomes, (2) Investigate the circumstances how the combination of MRI radiomics and clinical tests complements each other and is more powerful in early prediction of treatment outcomes. To achieve these aims, we will retrospectively collect a large data set of MM cases with baseline and follow-up MRI scans and clinical tests for development and validation of the DSS system. We will utilize advanced artificial intelligence (AI) techniques including recurrent neural networks and reinforcement learning to train predictive models with time serial MRI and clinical data acquired at multiple time points, which allows the trained models to be deployed flexibly to each individual time point for treatment assessment to facilitate early prediction. Furthermore, these advanced AI techniques can learn intertemporal dependencies from available data to compensate for the missing data or exams at single time points in serial exams which may occur in real-world clinical situation. With a flexible modular architecture design of our DSS system, we will investigate the inter- and intra-relationships between MRI and laboratory variables for better understanding of their complementarity in characterizing tumor burden during MM treatment and their association with treatment outcomes. As a final step, using an independent multi-institutional test set, we will validate the performance of the developed DSS in predicting the recurrence risk at an early time point during treatment.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $513,954 )
2026	2026	REGENTS OF THE UNIVERSITY OF MICHIGAN	1109 GEDDES AVE STE 3300	ANN ARBOR	MI	48109	WASHTENAW	USA	Cancer Detection and Diagnosis Research	000	3	12/8/2025	NON-COMPETING CONTINUATION	$513,954
														Subtotal = $513,954

Issue Date FY: 2025 ( Subtotal = $570,314 )
2025	2025	REGENTS OF THE UNIVERSITY OF MICHIGAN	1109 GEDDES AVE STE 3300	ANN ARBOR	MI	48109	WASHTENAW	USA	Cancer Detection and Diagnosis Research	001	2	6/3/2025	NON-COMPETING CONTINUATION	$57,032
2025	2025	REGENTS OF THE UNIVERSITY OF MICHIGAN	1109 GEDDES AVE, SUITE 3300	ANN ARBOR	MI	48109	WASHTENAW	USA	Cancer Detection and Diagnosis Research	000	2	11/18/2024	NON-COMPETING CONTINUATION	$513,282
														Subtotal = $570,314

Issue Date FY: 2024 ( Subtotal = $577,373 )
2024	2024	REGENTS OF THE UNIVERSITY OF MICHIGAN	1109 GEDDES AVE, SUITE 3300	ANN ARBOR	MI	48109	WASHTENAW	USA	Cancer Detection and Diagnosis Research	000	1	11/21/2023	NEW	$577,373
														Subtotal = $577,373

Grand Total All Awards = $1,661,641

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A framework for integrating MR imaging and clinical tests for prediction of outcomes in multiple myeloma treatment

Award Number: R01CA278898

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/01/2023

PERIOD OF PERFORMANCE END DATE: 11/30/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer